2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
We are pleased to announce that the European Society of Cardiology (ESC), together with the European Atherosclerosis Society (EAS), has published the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.
Since the publication of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular (CV) risk, there have been several randomized controlled trials that might change patient management ahead of the next scheduled full dyslipidaemia Guidelines.
This 2025 Focused Update addresses changes in recommendations for the treatment of dyslipidaemias based on new evidence published up until March 31, 2025.
- François Mach, ESC Chairperson, Konstantinos C. Koskinas, ESC Chairperson, Jeanine E. Roeters van Lennep, EAS Chairperson, Lale Tokgözoğlu, Task Force Co-ordinator, Lina Badimon, Colin Baigent, Marianne Benn, Christoph J. Binder, Alberico L. Catapano, Guy G. De Backer, Victoria Delgado, Natalia Fabin, Brian A. Ference, Ian M. Graham, Ulf Landmesser, Ulrich Laufs, Borislava Mihaylova, Børge Grønne Nordestgaard, Dimitrios J. Richter, Marc S. Sabatine, ESC/EAS Scientific Document Group, Document Reviewers, ESC National Cardiac Societies actively involved in the review process of the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, ESC Clinical Practice Guidelines (CPG) Committee, EAS Executive Committee
- Published August 29, 2025
- Atherosclerosis Journal, 2025. https://doi.org/10.1016/j.atherosclerosis.2025.120479
- European Heart Journal, 2025. https://doi.org/10.1093/eurheartj/ehaf190